These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29677073)

  • 1. Outcomes After Cardiac Transplant for Wild Type Transthyretin Amyloidosis.
    Rosenbaum AN; AbouEzzeddine OF; Grogan M; Dispenzieri A; Kushwaha S; Clavell A; Daly RC; Edwards BS
    Transplantation; 2018 Nov; 102(11):1909-1913. PubMed ID: 29677073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced trans-mitral A-wave velocity predicts the presence of wild-type transthyretin amyloidosis in elderly patients with left ventricular hypertrophy.
    Yamamura S; Izumiya Y; Ishida T; Onoue Y; Kimura Y; Hanatani S; Araki S; Fujisue K; Sueta D; Kanazawa H; Takashio S; Usuku H; Sugamura K; Sakamoto K; Yamamoto E; Yamamuro M; Yasuda H; Kojima S; Kaikita K; Hokimoto S; Ogawa H; Tsujita K
    Heart Vessels; 2017 Jun; 32(6):708-713. PubMed ID: 27882404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exercise Hemodynamics and Mitochondrial Oxidative Capacity in Disease Stages of Wild-Type Transthyretin Amyloid Cardiomyopathy.
    Ladefoged B; Pedersen AD; Seefeldt J; Nielsen BRR; Eiskjær H; Lichscheidt E; Clemmensen T; Gillmore JD; Poulsen SH
    J Am Heart Assoc; 2024 Jul; 13(13):e034213. PubMed ID: 38934860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure.
    Gagliardi C; Perfetto F; Lorenzini M; Ferlini A; Salvi F; Milandri A; Quarta CC; Taborchi G; Bartolini S; Frusconi S; Martone R; Cinelli MM; Foffi S; Reggiani MLB; Fabbri G; Cataldo P; Cappelli F; Rapezzi C
    Eur J Heart Fail; 2018 Oct; 20(10):1417-1425. PubMed ID: 30070416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
    Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH
    Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders.
    López-Sainz Á; de Haro-Del Moral FJ; Dominguez F; Restrepo-Cordoba A; Amor-Salamanca A; Hernandez-Hernandez A; Ruiz-Guerrero L; Krsnik I; Cobo-Marcos M; Castro V; Toquero-Ramos J; Lara-Pezzi E; Fernandez-Lozano I; Alonso-Pulpon L; González-López E; Garcia-Pavia P
    Amyloid; 2019 Sep; 26(3):156-163. PubMed ID: 31210553
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of Ventilatory Efficiency Slope as a Marker for Increased Mortality in Wild-Type Transthyretin Cardiac Amyloidosis.
    Yunis A; Doros G; Luptak I; Connors LH; Sam F
    Am J Cardiol; 2019 Jul; 124(1):122-130. PubMed ID: 31053293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transthyretin amyloid cardiomyopathy among patients with heart failure and preserved ejection fraction: the AMY score.
    Gioia G; Schrutka L; Jozwiak-Nozdrzykowska J; Kresoja KP; Gunold H; Klingel K; Thiele H; Bonderman D; Lurz P; Rommel KP
    ESC Heart Fail; 2024 Aug; 11(4):2172-2181. PubMed ID: 38613409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determining patterns of vascular function and structure in wild-type transthyretin cardiac amyloidosis. A comparative study.
    Stamatelopoulos K; Delialis D; Georgiopoulos G; Tselegkidi MI; Theodorakakou F; Dialoupi I; Bambatsias D; Petropoulos I; Vergaro G; Ikonomidis I; Tzortzis S; Briasoulis A; Kanakakis J; Trougakos I; Dimopoulos MA; Kastritis E
    Int J Cardiol; 2022 Sep; 363():102-110. PubMed ID: 35716935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated diagnostic approach to wild-type transthyretin cardiac amyloidosis with the use of high-sensitivity cardiac troponin T measurement and
    Ochi Y; Kubo T; Nakashima Y; Baba Y; Hirota T; Yamasaki N; Yamashita T; Ueda M; Ando Y; Kitaoka H
    J Cardiol; 2020 Jan; 75(1):12-19. PubMed ID: 31324572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study.
    Connors LH; Sam F; Skinner M; Salinaro F; Sun F; Ruberg FL; Berk JL; Seldin DC
    Circulation; 2016 Jan; 133(3):282-90. PubMed ID: 26660282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Echocardiographic assessment of right heart function in heart transplant recipients and the relation to exercise hemodynamics.
    Clemmensen TS; Eiskjaer H; Løgstrup BB; Andersen MJ; Mellemkjaer S; Poulsen SH
    Transpl Int; 2016 Aug; 29(8):909-20. PubMed ID: 27159372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Where Neurosurgery Meets Heart Failure: A Case Report of a Patient with Amyloid Transthyretin Wild Type in the Ligamentum Flavum and Cardiac Tissue with Bilateral Carpal Tunnel Syndrome.
    Dowd RS; Nail TJ; Arkun K; Kryzanski J; Soto O; Fogaren T; Harrington K; Patel A; Comenzo R; Riesenburger RI
    World Neurosurg; 2019 Nov; 131():104-107. PubMed ID: 31369882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic variation of the transthyretin gene in wild-type transthyretin amyloidosis (ATTRwt).
    Sikora JL; Logue MW; Chan GG; Spencer BH; Prokaeva TB; Baldwin CT; Seldin DC; Connors LH
    Hum Genet; 2015 Jan; 134(1):111-21. PubMed ID: 25367359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Therapeutic Modification on Outcomes in Heart Transplantation Over the Past Two Decades　- A Single-Center Experience in Japan.
    Yanase M; Iwasaki K; Watanabe T; Seguchi O; Nakajima S; Kuroda K; Mochizuki H; Matsuda S; Takenaka H; Ikura M; Tadokoro N; Fukushima S; Fujita T; Ishibashi-Ueda H; Nakatani T; Kitamura S; Kobayashi J; Tsujita K; Ogawa H; Fukushima N
    Circ J; 2020 May; 84(6):965-974. PubMed ID: 32350231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan.
    Yamada T; Takashio S; Arima Y; Nishi M; Morioka M; Hirakawa K; Hanatani S; Fujisue K; Yamanaga K; Kanazawa H; Sueta D; Araki S; Usuku H; Nakamura T; Suzuki S; Yamamoto E; Ueda M; Kaikita K; Tsujita K
    ESC Heart Fail; 2020 Oct; 7(5):2829-2837. PubMed ID: 32672425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin.
    Hanson JLS; Arvanitis M; Koch CM; Berk JL; Ruberg FL; Prokaeva T; Connors LH
    Circ Heart Fail; 2018 Feb; 11(2):e004000. PubMed ID: 29449366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy.
    Benson MD; Dasgupta NR; Rissing SM; Smith J; Feigenbaum H
    Amyloid; 2017 Dec; 24(4):219-225. PubMed ID: 28906150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The quintessential form of diastolic heart failure in older adults: Wild type transthyretin cardiac amyloidosis.
    Driggin E; Maurer MS
    Clin Cardiol; 2020 Feb; 43(2):171-178. PubMed ID: 31825134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.